Novartis | NOVN - Sales Revenues

Stock Price
119.04
Daily Change
1.84 1.57%
Monthly
0.69%
Yearly
27.60%
Q2 Forecast
114.36

Novartis reported $13.11B in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
AbbVie USD 15B 1.62B Mar/2026
Alcon AG USD 2.69B 10M Mar/2026
Almirall EUR 547.63M 12.83M Dec/2025
Amgen USD 8.62B 1.28B Mar/2026
AstraZeneca USD 15.29B 213M Mar/2026
Autolus Therapeutics Ltd USD 26.22M 1.93M Mar/2026
Bayer EUR 13.41B 1.97B Mar/2026
Biogen USD 2.25B 30M Mar/2026
Bristol-Myers Squibb USD 11.49B 1.01B Mar/2026
Eli Lilly USD 19.8B 500M Mar/2026
Fresenius EUR 5.74B 140M Mar/2026
Fresenius Medical Care EUR 4.61B 460M Mar/2026
Genmab DKK 1.06B 36M Dec/2025
Gilead Sciences USD 7B 930M Mar/2026
GlaxoSmithKline GBP 7.63B 991M Mar/2026
GRIFOLS EUR 1.7B 280M Mar/2026
Hikma Pharmaceutical USD 1.69B 863M Dec/2025
J&J USD 24.1B 500M Mar/2026
Lakefront Biotherapeutics EUR 6.5M 894.32M Mar/2026
Lonza CHF 3.58B 63M Jun/2025
Merck EUR 5.13B 120M Mar/2026
Merck USD 16.29B 110M Mar/2026
Novartis USD 13.11B 226M Mar/2026
Novartis USD 13.11B 750M Mar/2026
Novo Nordisk DKK 96.82B 17.68B Mar/2026
Orion EUR 417.7M 277.6M Mar/2026
Pfizer USD 14.5B 3.08B Mar/2026
Philips EUR 3.91B 1.19B Mar/2026
Recordati EUR 713.42M 51.42M Mar/2026
Regeneron Pharmaceuticals USD 3.6B 280M Mar/2026
Roche Holding CHF 15.65B 274.5M Dec/2025
Sanofi EUR 11.24B 60M Mar/2026
UCB EUR 4.25B 764M Dec/2025